Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients

@article{Funke2000PalliativeCI,
  title={Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients},
  author={I. Funke and M. Wiesneth and S. Platow and B. Kubanek},
  journal={Annals of Hematology},
  year={2000},
  volume={79},
  pages={132-137}
}
Abstract The efficiency and toxicity of treatment regimens for nonintensive cytoreduction in 57 outpatients with refractory acute leukemia (mean age 56 years, 51 AML, six ALL/AUL) were retrospectively studied. Seventeen patients received one treatment regimen, 19 patients two treatment regimens, and 21 patients three or more treatment regimens. The treatment regimens analyzed were 6-thioguanine p.o. (daily) (T), 6-thioguanine p.o. (4–7 days/week) + cytarabine s.c./i.v. (once a week) (T+C), 6… Expand
Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide
Mucositis: Perspectives and Clinical Practice Guidelines
  • 2004

References

SHOWING 1-10 OF 25 REFERENCES
Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients.
Mitoxantrone for refractory and relapsed acute leukemia
The Toxicity of Cytarabine
A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
Approaches to the therapy of relapsed acute myeloid leukemia.
TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKAEMIA WITH LOW DOSE ETOPOSIDE
...
1
2
3
...